SES O J SERVING TOPHOLOGICAL SES OFFICE AND PROPERTY OF THE PR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re the Application of:

Bradford J. Duft, et al.

Serial No.: 09/445,517

Filed: December 6, 1999

For: METHODS FOR TREATING OBESITY

Group Art Unit: 1645

Examiner: S. Devi

SEP - 1 MAY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.56, the following information is brought to the attention of the Examiner. The items are listed on the attached Form PTO/SB/08A and copies are enclosed for the convenience of the Examiner. Applicants respectfully request that these documents be made of record in the above-referenced application.

The item identified in this Supplemental Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be

CERTIFICATE OF MAILING (37 CFR §1.8 a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Name of Person Mailing Paper

Signature of Person Mailing Paper

Date of Deposit

C:\NrPortbl\SDILIB1\TMB\436336_1.DOC

construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Supplemental Information Disclosure Statement is being submitted under 37 CFR 1.97(c) (2). Enclosed is a check in the amount of \$180.00 to cover the fee pursuant to 37 CFR 1.17(p). The Commissioner is authorized to charge any additional fee required by this submission or to credit any over payment to counsel's Deposit Account No. 50-1273.


Respectfully submitted,

Lisa M. McGeehan

Reg. No. 41185

BROBECK, PHLEGER & HARRISON LLP 12390 El Camino Real San Diego, CA 92130-2081 (858) 720-2500 Phone

(858) 720-2555



PTO/SB/08A (08-00)

Ap. J for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	Co	omplete if Known	
INFORMATION DISCLOSURE	Application Number	09/445,517	
STATEMENT BY APPLICANT	Filing Date	December 6, 1999	·
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Bradford J. Duft	
(use as many sheets as necessary)	Group Art Unit	1645	É
/ 15th 2 /	Examiner Name	Devi, S.	3
Sheet of	Attorney Docket Number		空

		NON PATENT LITERATURE DOCUMENTS	- 3
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, social supposition catalog etc.) date page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Initials*	NO.	KOLTERMAN et al., "Effect Of 14 Days' Subcutaneous Administration Of The Human Amylin Analogue, Pramlintide (AC137) On An Intravenous Insulin Challenge And Response To A Standard Liquid Meal In Patients With IDDM," <u>Diabetologia</u> , 39(4):492-9 (1996)	
		KONG et al., "Infusion Of Pramlintide, A Human Amylin Analogue, Delays Gastric Emptying In Men With IDDM," <u>Diabetologia</u> , 40(1):82-88 (1997)	
		KONG et al., "The Effect Of Single Doses Of Pramlintide On Gastric Emptying Of Two Meals In Men With IDDM," <u>Diabetologia</u> , 41(5):577-83 (1998)	
		NYHOLM et al., "Acute Effects Of The Human Amylin Analog AC137 On Basal And Insulin-Stimulated Eugycemic And Hypoglycemic Fuel Metabolism In Patients With Insulin-Dependent Diabetes Mellitus," <u>J. Clin. Endocrinol. Metab.</u> , 81(3):1083-89 (1996)	
		SCHMITZ et al., "Effects Of Amylin And The Amylin Agonist Pramlintide On Glucose Metabolism," <u>Diabetic Med.</u> , 14(2):S19-S23 (1997)	
		THOMPSON et al., "Effects Of 4 Weeks' Administration Of Pramlintide, A Human Amylin Analogue, On Glycaemia Control In Patients With IDDM: Effects On Plasma Glucose Profiles And Serum Fructosamine Concentrations," <u>Diabetologia</u> , 40(11):1278-1285 (1997)	
		THOMPSON et al., "Pramlintide: A Human Amylin Analogue Reduced Postprandial Plasma Glucose, Insulin, And C-Peptide Concentrations In Patients With Type 2 Diabetes." Diabetic Med., 14(7):547-55 (1997)	
		WANG et al., "Influence Of Islet Amyloid Polypeptide And The 8-37 Fragment of Islet Amyloid Polypeptide on Insulin Release From Perifused Rat Islets," <u>Diabetes</u> , 42(2):330-5 (1993)	

Examiner	Date
Signature	Considered
Olg. Later 9	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.